---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-24-000070"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T06:52:09.116608+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Autolus presents FELIX update: 78% ORR, 40% ongoing remission without SCT, median OS 23.8 months

## Summary
- ORR 78% (99/127); median EFS 11.9 months, median OS 23.8 months; 12-month OS rate 61.1%.
- 40% of responders in ongoing remission without SCT or other therapy at median 21.3 months follow-up.
- Ongoing CAR T persistence associated with 2.7x lower relapse/death risk vs. loss of persistence.
- Consolidative SCT after obe-cel did not appear to improve EFS or OS in responders.
- BLA under FDA review with PDUFA target action date November 16, 2024.

## SEC filing metadata
- accession: 0001730463-24-000070
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000070/0001730463-24-000070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000070/autl-20240531.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-24-000070
- JSON: https://secwatch.observer/filing/0001730463-24-000070.json
- Plain text: https://secwatch.observer/filing/0001730463-24-000070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.